An experienced team that has
built and exited therapeutics companies
Deep PTH biology and protein-chemistry manufacturing, paired with venture-stage company-building, and supported by renowned advisors across dermatology and regenerative medicine.
The operating team.
Decades of combined experience spanning drug development, protein-chemistry manufacturing, and the clinical science of parathyroid hormone, with a track record of advancing early-stage assets to successful exits.
David Leffell, MD
A track record of successful executive leadership, leading Flourish's strategy and execution.
Tim Bertram, PhD
Biotech founder with multiple successful exits; inventor of numerous patents with a strong track record of capital investments.
Robyn Goforth, PhD
20 years' experience in protein chemistry and manufacturing; principal investigator on more than $15 million in federal grants.
Rob Gensure, MD
Chief of Pediatric Endocrinology, Children's Hospital at Dartmouth-Hitchcock. An international expert on parathyroid hormone.
Governance
Board of Directors
An experienced board spanning venture investment, company-building, and therapeutic development.
David Scheer
Board Chair · President, Scheer & Company
J. David Owens
Director · Partner, Bowman Ventures
David Leffell, MD
Director · CEO, Flourish Biologics
Calvin Goforth, PhD
Director · CEO, VIC Tech
Scientific Advisory Board
Leading voices in dermatology.
Clinicians and researchers from the institutions defining the field of hair-loss medicine.
Brett King, MD, PhD
Dermatology Physicians of Connecticut
Ali Jabbari, MD, PhD
Endowed Chair in Dermatology, University of Iowa
Maryanne Senna, MD
Dermatology, Harvard Medical School
Britt Craiglow, MD
Dermatology Physicians of Connecticut
Natasha Mesinkovska, MD, PhD
Dermatology, UC Irvine School of Medicine
A first-in-class regenerative therapy for androgenetic alopecia and other forms of hair loss — building quality of life.
© 2026 Flourish Biologics
This website is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Forward-looking statements regarding the company’s research and development are subject to risks and uncertainties.